The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes ...
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 501.82% and ...
Elon Musk has admitted to taking a weight-loss drug in a Christmas Day post on X, formerly Twitter, as he shared a picture of ...
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...
Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next two to three months.
The FDA on Thursday confirmed that a shortage of Eli Lilly’s obesity drug tirzepatide has been resolved, a move that will put ...
The FDA first approved Zepbound to treat obesity in November 2023. Its active ingredient, tirzepatide, was previously ...
The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a ...